Patient Guide: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 227 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT04224493
Status: 🟢 Enrolling Now
Condition: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Phase: PHASE3

Find a Study Location Near You

This study is available at 227 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Mobile, Alabama
  • Tucson, Arizona
  • Cerritos, California
  • • And 224 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily